Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers ...